Journal Mobile Options
Table of Contents
Vol. 143, Suppl. 1, 2007
Issue release date: June 2007
Int Arch Allergy Immunol 2007;143:89–94

Expression of Interleukin-17F in a Mouse Model of Allergic Asthma

Suzuki S. · Kokubu F. · Kawaguchi M. · Homma T. · Odaka M. · Watanabe S. · Ieki K. · Matsukura S. · Kurokawa M. · Takeuchi H. · Sasaki Y. · Huang S.-K. · Adachi M. · Ota H.
aFirst Department of Internal Medicine, and bSecond Department of Pathology, Showa University School of Medicine, Tokyo, and cDepartment of Respiratory Medicine, Showa University Fujigaoka Hospital, Kanagawa, Japan; dJohns Hopkins University, Asthma and Allergy Center, Baltimore, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Interleukin (IL)-17F is a recently discovered cytokine and is derived from a panel of limited cell types, such as activated CD4+ T cells, basophils, and mast cells. IL-17F is known to induce several cytokines and chemokines. However, its involvement in airway inflammation has not been well understood. To this end, the expression of IL-17F and the inhibitory effects of glucocorticoids on its expression in a mouse model of asthma were examined. Methods: Five-week-old BALB/c male mice were sensitized by intraperitoneal injection (i.p.) of ovalbumin (OVA) with alum, and challenged by daily inhalation of aerosolized 1% OVA. 24 h after last challenge (OVA/OVA), the expression of IL-17F was examined in lung tissues by immunohistochemistry and reverse-transcription polymerase chain reaction. Control mice were sensitized and challenged with saline (Sham/Sham). In addition, a group of OVA-sensitized mice received i.p. injection of water-soluble dexamethasone (DEX) in saline 1 h before OVA challenge (OVA/DEX). Results: In sham-challenged mice, IL-17F was not expressed in the lungs, while, in contrast, IL-17F was predominantly expressed in bronchial epithelial cells in addition to the infiltrating inflammatory cells in OVA/OVA mice. Further, the expression of IL-17 F was significantly attenuated by the treatment of mice with DEX. Conclusion: These results suggest that bronchial epithelium-derived IL-17F may represent a new pharmacological target for glucocorticoids and may play a role in allergic asthma.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ: Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483–5486.
  2. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC. Wang W, Wathen K, Hodge V, Fisher CL, Olsen H, Ruben SM, Knyazev I, Cho YH, Kao V, Wilkinson KA, Carrell JA, Ebner R: A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000;275:19167–19176.
  3. Li H, Chen J, Huang A, Stinson J, Heldens S, Foster J. Dowd P, Gurney AL, Wood WI: Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000;97:773–778.
  4. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R: Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002;169:642–646.
  5. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS. Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL: IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001;276:1660–1664.
  6. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, Liu MC, Krishnaswamy G, Germino G, Huang SK: Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol 2001;167:4430–4435.
  7. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA: IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20:5332–5341.
  8. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, Hromas R: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001;167:4137–4140.
  9. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, Maeda Y, Konno S, Huang SK, Nishimura M, Adachi M: Interleukin-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006;117:795–801.
  10. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB: Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-γ cytokine gene experssion. Am Rev Respir Dis 1993;148:401–406.
  11. Wang JH, Devalia JL, Xia C, Sapsford RJ, Davies RJ: Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am J Respir Cell Mol Biol 1996;14:27–35.
  12. Yamada H, Yamaguchi M, Yamamoto K, Nakajima T, Hirai K, Morita Y, Sano Y, Yamada H: Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. Allergy 2000;55:392–397.
  13. Shen H, O’Byrne PM, Ellis R, Wattie J, Tang C, Inman MD: The effect of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice. Am J Respir Crit Care Med 2002;166:146–153.
  14. Nagai H, Yamaguchi S, Inagaki N, Tsuruoka N, Hitoshi Y, Takatsu K: Effect of anti-IL-5 monoclonal antibody on allergic bronchial eosinophilia and airway hyperresponsiveness in mice. Life Sci 1993;53:PL243–PL247.

    External Resources

  15. Kurokawa M, Kokubu F, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M, Watanabe S, Takeuchi H, Akabane T, Asano K, Iwase M, Honma I, Adachi M: Effects of corticosteroid on the expression of thymus and activation-regulated chemokine in a murine model of allergic asthma. Int Arch Allergy Immunol 2005;137(suppl 1):60–68.
  16. Alexandre T, Ahmed EH, Claude B: Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. Am J Physiol 2000;279:L1120–L1128.
  17. Polito AJ, Proud D: Epithelia cells as regulators of airway inflammation. J Allergy Clin Immunol 1998;102:714–718.
  18. Kawaguchi M, Onuchic LF, Huang SK: Activation of extracellular signal-regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is involved in signaling of a novel cytokine, ML-1. J Biol Chem 2002;277:15229–15232.
  19. Kawaguchi M, Kokubu F, Matsukura S, Ieki K, Odaka M, Watanabe S, Suzuki S, Adachi M, Huang SK: Induction of C-X-C chemokines, growth-related oncogene alpha expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (inter-leukin-17F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 pathway. J Pharmacol Exp Ther 2003;307:1213–1220.
  20. Kawaguchi M, Kokubu F, Odaka M, Watanabe S, Suzuki S, Ieki K, Matsukura S, Kurokawa M, Adachi M, Huang SK: Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. J Allergy Clin Immunol 2004;114:444–450.
  21. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK: IL-17 cytokine family. J Allergy Clin Immunol 2004;114:1265–1273.
  22. Barnes PJ: Corticosteroid effects on cell signalling. Eur Respir J 2006;27:413–426.
  23. Dulos J, Kaptein A, Kavelaars A, Heijnen C, Boots A: Tumour necrosis factor-alpha stimulates dehydroepiandrosterone metabolism in human fibroblast-like synoviocytes: a role for nuclear factor-kappaB and activator protein-1 in the regulation of expression of cytochrome p450 enzyme 7b. Arthritis Res Ther 2005;7:R1271–R1280.

    External Resources

  24. Oda N, Canelos PB, Essayan DM, Plunkett BA, Myers AC, Huang SK: Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response. Am J Respir Crit Care Med 2005;171:12–18.
  25. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TT, Brieland JK, Zurawski SM, Chapman RW, Zurawski G, Coffman RL: New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002;169:443–453.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50